Toggle navigation
Home
Search
Services
Blog
Contact
About
Novel Polymorphic Markers for Genetic Analyses
Schumm, James W.
Promega Corporation, Madison, WI, United States
Search 3 grants from James Schumm
Search grants from Promega Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
UMB Postbaccalaureate Research Education Program
Local food sources around home and school and adolescent dietary intake
Redox Regulation of Multidrug Resistance Gene Expression
Lab Sup. for AIDS Vaccine & Other Prevent. Clinical Tria
Major Histocompatibility Complex in Human Disease
Recently added grants:
Investigating the role of Strada signaling in promoting AML chemoresistance
Dectin-1 signaling drives pancreatic oncogenesis by inducing macrophage-mediated adaptive immune suppression
Metabolic Regulation ofPD-L1 in CD11c+ Cells
Explore the therapeutic potential of small-molecule immune modulators
Inhibiting Emergence and Progression of Castration-resistant Prostate Cancer through Enforcement of Senescence and Alteration of the Tumor Microenvironment
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44MH052940-02
Application #
2252922
Study Section
Special Emphasis Panel (ZRG7-SSS-2 (12))
Project Start
1994-09-30
Project End
1998-06-30
Budget Start
1996-07-01
Budget End
1997-06-30
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Institution
Name
Promega Corporation
Department
Type
DUNS #
City
Madison
State
WI
Country
United States
Zip Code
53711
Related projects
NIH 1997
R44 MH
Novel Polymorphic Markers for Genetic Analyses
Schumm, James W. / Promega Corporation
NIH 1996
R44 MH
Novel Polymorphic Markers for Genetic Analyses
Schumm, James W. / Promega Corporation
Comments
Be the first to comment on James Schumm's grant